About Us

Who We Are

Metabolomic Technologies Inc. is a fast growing company specializing in the development of novel metabolomics-based diagnostics for the healthcare market.

Our lead product, PolypDx™ is the first and only urine-based screening test for the detection and prevention of colorectal cancer. 
Meet our team here

Where the Innovation Started

We are the legacy of our founder, Dr. Richard Fedorak.  Dr. Fedorak was a visionary health sciences entrepreneur and world leading gastroenterologist.  It was his vision that we can one day rid the world of colorectal cancer.  Dr. Fedorak and Dr. Haili Wang had the idea to develop an easier, non-invasive way to detect colorectal cancer in its earliest stages.  Through Dr. Fedorak's leadership and passion, an innovative new way to screen for cancer was born.

Our team at MTI share in this vision, and will continue to take on the challenge of bringing innovation to patients all around the world.  In us and our company, his legacy will live on.

 

Our Award-winning Flagship Product

Our flagship product, PolypDx™, is the first and only urine-based test with a high sensitivity for detecting adenomatous polyps, the precursor to colorectal cancer. PolypDx™ provides healthcare professionals with a tool for early screening and detection, enabling the timely removal of polyps before they progress to colorectal cancer, thereby preventing cancer in the first place.

View our accolades

Milestone Timeline

2014

1000-Patient Discovery Trial Completed

2016

Validation Trials Completed

2017

2M CAD Seed Round

2017

PolypDx™ LDT Launched

2018

Canadian Assessment of PolypDx™

2018

2018 Economic Model showing PolypDx™ is cost-effective

2019

US Patent Issued - Completing global IP coverage

2019

Discovery & Validation on additional CRC markers

2019

Closed 3.2M USD Series A Round